Nifty Pharma Slides 1.02% - Gland Pharma, Aurobindo, Lupin Among Top Losers

Thursday, August 28, 2025: The Nifty Pharma Index was under slight pressure on Thursday morning, shedding 225.35 points (1.02%), reaching 21764.65 at 10:25 AM. The main reason for the decline is attributed to broad-based selling witnessed among the constituent stocks, with 17 shares in the red against only three gainers.

The index opened at 22,043.8, hit a day’s high of 22,051.8, and slipped to a low of 21,732.35, compared to its previous close of 21,990.0. It consolidated a bit by 12:00 PM and reached 21836 points (0.70% down from the previous day’s close).

Market Performance Snapshot

At 10:25 AM, Natco Pharma rose 1.39% on news of its Bosentan tablets launch in the US, which comes with 180-day exclusivity. In comparison, Biocon gained 0.57% after receiving tentative US FDA approval for Sitagliptin tablets. Granules India was up 0.31%. On the downside, Sun Pharma (-1.77%), Aurobindo Pharma (-1.47%), Lupin (-1.39%), Ajanta Pharma (-1.98%), Ipca Labs (-2.17%), and Gland Pharma (-2.31%) led the losses.

However, by 12:00 PM, as the market consolidated a bit and the index gained some points, six out of twenty constituents traded in green (Granules India increased by 1.50%), whereas the highest losses were incurred by Gland Pharma (-2.20%)

Broad Market Context

The selling pressure can be linked with the global trade tensions, including the additional US tariffs on Indian exports. As the markets were closed yesterday, the impact of the effective date is felt today with increased selling pressure across sectors, coupled with higher foreign investment outflows and market volatility.

REF:https://www.nseindia.com/market-data/live-equity-market?symbol=NIFTY PHARMA

https://nsearchives.nseindia.com/corporate/GLAND_26082025115029_Press_Release_26082025_final.pdf

https://nsearchives.nseindia.com/corporate/AUROPHARMA_26082025093517_LtrToSEsCurateqApproval26082025.pdf

https://nsearchives.nseindia.com/corporate/Biocon2_26082025205808_SE26082025.pdf

https://nsearchives.nseindia.com/corporate/NATCOPHARM_20082025104731_DisclosuretoSE20082025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations